Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:04:42 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:BGNE - BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BGNE - Q0.6131.00·138.000.1131.96+0.100.1126.016,6062,522131.40  136.00  131.40266.665  131.279416:02:12Mar 1415 min RT 2¢

Recent Trades - Last 10 of 2522
Time ETExPriceChangeVolume
16:02:12Q131.960.10138
16:01:20Q131.960.10109
16:00:08Q131.960.10302
16:00:08Q131.960.1070
16:00:08Q131.960.101,177
16:00:07Q131.960.10391
16:00:07Q131.960.101
16:00:02Q131.960.1053
16:00:02Q131.960.107
16:00:02Q131.960.101

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-14 16:28U:BGNENews ReleaseBeiGene Receives FDA Approval for TEVIMBRA(TM) for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
2024-03-13 08:00U:BGNENews ReleaseFirst Doses of BRUKINSA(TM) provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
2024-03-07 17:19U:BGNENews ReleaseBeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
2024-03-06 06:00U:BGNENews ReleaseBeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
2024-02-29 10:00U:BGNENews ReleaseBeiGene Announces New Efficacy Analysis Comparing BRUKINSA(TM) vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
2024-02-28 08:05U:BGNENews ReleaseBeiGene to Present at Upcoming Investor Conferences
2024-02-27 06:00U:BGNENews ReleaseBeiGene's Biologics License Application for TEVIMBRA(TM) (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
2024-02-26 06:00U:BGNENews ReleaseBeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-26 05:00U:BGNENews ReleaseBeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
2024-01-23 06:00U:BGNENews ReleaseBeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
2023-12-22 06:00U:BGNENews ReleaseFDA Approves Label Update for BRUKINSA ‚ ® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
2023-12-21 06:01U:BGNENews ReleaseBeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-29 16:01U:BGNENews ReleaseBeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
2023-11-28 06:00U:BGNENews ReleaseBeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
2023-11-21 06:00U:BGNENews ReleaseBeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
2023-11-17 06:00U:BGNENews ReleaseBeiGene Receives European Commission Approval for BRUKINSA ‚ ® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
2023-11-09 16:01U:BGNENews ReleaseBeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
2023-11-08 06:00U:BGNENews ReleaseBeiGene to Present at the Jefferies London Healthcare Conference
2023-10-20 06:00U:BGNENews ReleaseBRUKINSA ‚ ® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
2023-10-17 16:01U:BGNENews ReleaseBeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)